PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Disappointment”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 253 records · Page 14Linked to original sources
PubMed1999

Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.

OBJECTIVE: To evaluate the longterm effectiveness of disease modifying antirheumatic drugs (DMARD) in an inception cohort of patients with rheumatoid arthritis (RA) seen by rheumatologists. METHODS: We performed a retrospective audit of the records of patients with onset of RA between January 1985 and June 1994. Charts were reviewed from the time of diagnosis to the last consult. Survival analysis was performed using Kaplan-Meier and Cox proportional hazard regression to adjust for potential confounders. RESULTS: A total of 2296 DMARD therapies were analyzed. Roughly half were started within 2 years of disease onset. By 16 months, 50% of the DMARD therapy courses had been discontinued, and after 4.5 years 75% had been discontinued. Over all, methotrexate (MTX) had the highest probability of continuation. After roughly 3 years 50% of patients were still receiving MTX, compared to one-third of patients who received antimalarials or intramuscular gold, 30% D-penicillamine, 25% sulfasalazine, and 18% oral gold. After 6 years, when considering all DMARD together, only 20% of the therapies had not been discontinued, with no substantial differences between drugs. Toxicity from gold compounds occurred within the first 18 months of therapy and stabilized thereafter. For MTX, withdrawals due to toxicity continued throughout therapy. CONCLUSION: This is the largest observational study examining the longterm termination rates of DMARD in patients followed from the time of their initial consult. Our results confirm previous reports of short therapeutic times, even for patients treated early in the course of their disease. MTX appears to be the best drug within the first 5 years of disease. These differences, however, decrease in the longer term. It is unclear whether the results observed for MTX within the first years of therapy translate to better health status in the longer term when compared to other DMARD.

Antirheumatic Agents↗
PubMed1999

Radial tunnel release and tennis elbow: disappointing results?

In a retrospective study, 19 patients with 20 decompressions of the posterior interosseous nerve for radial tunnel syndrome were reviewed. The results were evaluated using Roles and Maudsley's criteria; they were found to be consistent with those previously reported: i.e. 75% favorable outcomes. Despite this finding only 8 patients (40%) stated they were satisfied. The main reason was residual pain. Shorter delay between the onset of symptoms and surgical treatment as well as simultaneous release of the lateral epicondylar muscles was found to influence positively patient satisfaction. These findings suggest that the scoring system used in the present study and also in previous studies is inappropriate. They also cast some doubt on the role of compression of the posterior interosseous nerve in the pathogenesis of chronic lateral elbow pain.

Adult↗
PubMed2000

Spermicide disappoints.

Explore the source record for details and available documents.

Disease Transmission, Infectious↗
PubMed2001

[Children with cancer--great progress, a lot of good news and some disappointments].

Each year, between 125 and 150 children under the age of 15 develop cancer in Norway. More than half of the children are less than five years of age at diagnosis. The malignancy is often of an embryonal origin and the disease spectrum very different from that in adults. Our progress in understanding and treating childhood malignancies is one of the success stories in paediatrics and in cancer biology and management. In the Nordic countries, about three of four children with cancer are cured, but the progress is different in different disease groups. For some malignancies, survival is close to 100%, while progress for other types have been much slower. However, cancer is still the main cause of death in children above one year of age who die of a disease. The progress has its price. The treatment is often intensive, with great morbidity and a definite mortality. Late effects are also of great concern. A more specific therapy targeted against the malignant cell, with less damage to normal cells, has long been our goal. Progress in recent years in the understanding of the malignant cells has now given the first definite examples that such targeted therapy may soon become a reality.

Adolescent↗